Apex Labs, launches advanced Supra Bioavailable Itraconazole 65 and 130 mg capsules

New Delhi,  July 1, 2022: Apex Laboratories Pvt. Ltd., one of India’s leading pharmaceutical companies based in Chennai has launched an advanced form of Itraconazole Capsules Supra Bioavailable 65 and 130 mg, a potent therapeutic choice to effectively control fungal infections. Supra Bioavailable Itraconazole capsules deliver a higher percentage (90%) of active medicine to the biological system, at a lesser dose. This advanced preparation also ensures lesser inter-individual variability which might translate into enhanced efficacy in the management of fungal infections.
 
Fungal infections are causing a huge burden in our healthcare ecosystem because of their worldwide distribution and person-to-person transmission. Fungal infections are broadly classified as superficial, deep and systemic (circulate throughout the body). Their effects range from superficial infections of the skin, hair and nails to scattered infections of the brain, heart, liver, lungs, spleen and kidneys.
 
Superficial mycoses of skin, nails and hair are among the common fungal infections and World Health Organization (WHO) reported their prevalence rate as 25% and it varies for occupational groups, gender and age groups.
 
Itraconazole capsule has become an oral treatment of choice for superficial fungal diseases. Itraconazole is widely considered even for the treatment of conditions such as Blastomycosis, Histoplasmosis & Aspergillosis.
 
“Although Itraconazole is an effective agent for fungal infection, studies state that, it has limitations such as poor absorption and variability in its blood concentrations, and for any medicine to produce a desired clinical effect, its absorption should be optimal with minimal inter-individual variability,” said Vishagan, Director, Apex Laboratories Pvt. Ltd.